Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

bz_pharma_briefs

Biotech

News

Health Care

Movers

Trading Ideas

General

KURA

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Baidu Photo by testing on Shutterstock

Earnings

Equities

Eurozone

Commodities

Markets

BIDU

CLCO

PYXS

QUBT

SNOW

Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results

oil-prices-5079975

Intraday Update

Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings

Kura Oncology Inc

Kura Sushi Inc

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA Inc

Kuraray Co Ltd

Press Releases

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Management

Kura Oncology Announces Senior Executive Promotions

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

KYKOY

TYO:4151

AnaptysBio

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

LENZ Therapeutics

MeiraGTx Hldgs

Opthea Limited - American Depositary Shares

Opthea

Organogenesis Hldgs

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Relay Therapeutics

Sana Biotechnology

Sionna Therapeutics

Tyra Biosciences

Valneva

Verve Therapeutics

HC Wainwright & Co.

JMP Securities

Wedbush

Scotiabank

B of A Securities

Comments

Kura Oncology

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga